ClinicalTrials.gg
SuspendedNCT05155332Updated Nov 10, 2026

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

A Phase 1 interventional study of BI 1831169 and anti-PD-1 antibody in Solid Tumors, sponsored by Boehringer Ingelheim. Suspended at 34 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Why this study was suspended
Sponsor decision - temporary enrolment hold as a precautionary measure following a safety event.
Updated Nov 10, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a type of antibody called a checkpoint inhibitor (anti-PD-1 antibody). Another purpose is to check whether the study treatment can fight cancer. In this study, BI 1831169 is given to people for the first time.

This study has 2 parts. In Part 1, participants get BI 1831169 alone for up to 3 months. In Part 2, participants get BI 1831169 in combination with a checkpoint inhibitor. Participants who take the combination treatment get BI 1831169 for up to 3 months and a checkpoint inhibitor for up to 1 year. BI 1831169 is given as an injection into the tumor, or as an infusion into the vein, or both (injection and infusion). Checkpoint inhibitors are given as an infusion into a vein. Participants get the medicines about every 3 weeks. This is called a treatment cycle.

Participants visit the site study site regularly. The number of study visits vary based on the study phase and treatment response. Some visits include an overnight stay. The doctors regularly check the participants' health and monitor the tumors. The doctors also take note of any health problems that could have been caused by the study treatment.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced, unresectable and/or or solid tumors
  • At least one or two accessible lesions, one with a minimum lesion diameter for injection of BI 1831169 (where applicable), and one which is amenable to (where applicable). Lesions must either be easily accessible or, if not easily accessible, patient must be willing to undergo repeated procedures (e.g., image guided procedures) for both biopsies and injections of BI 1831169
  • Has failed conventional treatment or for whom no therapy of proven efficacy exists, who is not eligible for established treatment options. Patient must have exhausted available treatment options known to prolong survival for their disease. This criterion does not apply to the specific indications in Part 2.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Vesicular stomatitis virus (VSV)-based agents
  • Concomitant medication or condition considered a high risk for complications from injection or as per the Investigator's judgement
  • Presence of
  • Presence of (HIV) meeting certain criteria, active disease or chronic active infection ( or B virus (HCV/))
  • Chronic use, regardless of daily dose Further exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Part 1 (Monotherapy): Arm A

    Drug: BI 1831169

  • Experimental
    Part 1 (Monotherapy): Arm B

    Drug: BI 1831169

  • Experimental
    Part 1 (Monotherapy): Arm C

    Drug: BI 1831169

  • Experimental
    Part 2 (Combination therapy): Arm D

    Drug: BI 1831169 · Drug: anti-PD-1 antibody

  • Experimental
    Part 2 (Combination therapy): Arm E

    Drug: BI 1831169 · Drug: anti-PD-1 antibody

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1.1, Dose escalation/Confirmation: Occurrence of Dose limiting toxicities (DLTs) during the mono Maximum tolerated dose (MTD) evaluation period

    Part 1 (Monotherapy).

    Time frame: up to 21 days

  2. Part 1.2, Dose expansion: Objective response (OR) defined as best overall response (BOR) of confirmed intratumoral immunotherapy complete response (itCR) or confirmed intratumoral immunotherapy partial response (itPR)

    BOR is defined according to Response Criteria for Intratumoral Immunotherapy in Solid Tumors (itRECIST). BOR will consider all tumor assessments from first administration of trial medication until disease progression or death (whichever occurs first) or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.

    Time frame: up to 49 months

  3. Part 2.1, Dose escalation/Confirmation: Occurrence of Dose limiting toxicities (DLTs) during the combination Maximum tolerated dose (MTD) evaluation period

    Part 2 (Combination Therapy).

    Time frame: up to 21 days

  4. Part 2.2, Dose Expansion: Objective response (OR) defined as best overall response (BOR) of confirmed immunotherapy complete response (iCR) or confirmed partial response (iPR)

    BOR is defined according to Response Criteria for Intratumoral Immunotherapy in Solid Tumors (itRECIST) by Investigator's assessment. BOR will consider all tumor assessments from first administration of trial medication until disease progression, death, last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent (whichever occurs first).

    Time frame: up to 49 months

Secondary outcomes

  1. Part 1.1, Dose escalation/Confirmation: Occurrence of DLTs during the on-treatment period

    Time frame: up to 49 months

  2. Part 1.1, Dose escalation/Confirmation: Occurrence of adverse events during the on-treatment period

    Time frame: up to 49 months

  3. Part 1.2, Dose expansion: Occurrence of adverse events during the on-treatment period

    Time frame: up to 49 months

  4. Part 1.2, Dose expansion: Occurrence of DLTs during the mono MTD evaluation period

    Time frame: up to 49 months

  5. Part 2.1, Dose escalation/Confirmation: Occurrence of DLTs during the on-treatment period

    Time frame: up to 49 months

  6. Part 2.1, Dose escalation/Confirmation: Occurrence of adverse events during the on-treatment period

    Time frame: up to 49 months

  7. Part 2.2 - Dose Expansion by Indication, All Arms: Occurrence of adverse events during the on-treatment period

    Time frame: up to 49 months

  8. Part 2.2 - Dose Expansion by Indication, Arms D and E: Duration of objective response (DoR)

    DoR is defined as the time from first documented iCR or iPR according to iRECIST until the earliest of disease progression by Investigator's assessment or death among patients with OR.

    Time frame: up to 49 months

  9. Part 2.2, Dose Expansion by Indication, Arms D and E: Disease control (DC)

    DC is defined as a BOR of iCR, iPR or immunotherapy stable disease (iSD), with BOR defined according to iRECIST by Investigator's assessment.

    Time frame: up to 49 months

  10. Part 2.2, Dose Expansion by Indication, Arm E: Progression-Free Survival (PFS) rate at 4 months (PFS-4)

    PFS-4 is defined as the proportion of patients who are alive and without progression by 4 months from the start of treatment. PFS is assessed by the Investigator using iRECIST.

    Time frame: up to 4 months

07

Study locations

34 sites
  • Banner MD Anderson Cancer Center-Gilbert-55251
    Gilbert, Arizona 85234, United States
  • University of Arizona
    Tucson, Arizona 85719, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Providence St. John's Health Center
    Santa Monica, California 90404, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • M Health Fairview University of Minnesota Medical Center
    Minneapolis, Minnesota 55455, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157, United States
  • Prisma Health
    Greenville, South Carolina 29605, United States
  • Tennessee Oncology, PLLC - Elliston Place Plaza DDU
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Southern Oncology Clinical Research Unit
    Bedford Park, South Australia 5062, Australia
  • Peninsula Haematology & Oncology
    Frankston, Victoria 3199, Australia
  • Medical University of Innsbruck
    Innsbruck, 6020, Austria
  • Salzburg Cancer Research Institute
    Salzburg, 5020, Austria
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • INS Bergonie
    Bordeaux, 33000, France
  • HOP Timone
    Marseille, 13385, France
  • CTR Eugène Marquis
    Rennes, 35042, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Hospital Duran i Reynals
    L'Hospitalet de Llobregat, 08907, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
  • University Hospital Geneva
    Geneva, 1205, Switzerland
08

References and documents

Publications

  • Porosnicu M, Quinson AM, Crossley K, Luecke S, Lauer UM. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors. Future Oncol. 2022 Aug;18(24):2627-2638. doi: 10.2217/fon-2022-0439. Epub 2022 Jun 14. PubMed 35699077 ↗

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2022 (actual). Primary completion is estimated for Jul 2028, 75 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2027 → Jul 2028 and completion Oct 2028 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Dec 13, 2021
StartActual
Mar 28, 2022
Primary completionEst.
Jul 18, 2028was Dec 2027
CompletionEst.
Feb 6, 2029was Oct 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 1 site removed
Show 8 added (6 United States, 1 Australia, 1 Italy)
  • Southern Oncology Clinical Research Unit · Bedford Park, Australia
  • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
  • University of Miami · Miami, United States
  • Winship Cancer Institute · Atlanta, United States
  • University of Louisville · Louisville, United States
  • Prisma Health · Greenville, United States
  • Tennessee Oncology, PLLC - Elliston Place Plaza DDU · Nashville, United States
  • Virginia Commonwealth University · Richmond, United States
Show 1 removed
  • Istituto Di Candiolo · Candiolo (TO), Italy
across 3 updates, Sep 30, 2026 – Nov 10, 2026
Primary completion
Dec 13, 2027→Jul 18, 2028
Nov 10, 2026
Study completion
Oct 31, 2028→Feb 6, 2029
Nov 10, 2026
Show all 4 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • Virginia Commonwealth University · Richmond, United States
    Primary completion Dec 13, 2027→Jul 18, 2028
    Study completion Oct 31, 2028→Feb 6, 2029
    + 1 other change: verification date
  2. Oct 27, 2026
    5 sites added
    Show 5 added (5 United States)
    • University of Miami · Miami, United States
    • Winship Cancer Institute · Atlanta, United States
    • University of Louisville · Louisville, United States
    • Prisma Health · Greenville, United States
    • Tennessee Oncology, PLLC - Elliston Place Plaza DDU · Nashville, United States
  3. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  4. Sep 30, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Australia, 1 Italy)
    • Southern Oncology Clinical Research Unit · Bedford Park, Australia
    • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
    Show 1 removed
    • Istituto Di Candiolo · Candiolo (TO), Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05155332
Responsible party
Sponsor
First posted
Dec 13, 2021
Start date
Mar 28, 2022
Primary completion
Jul 18, 2028 (estimated)
Completion
Feb 6, 2029 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion